Adalimumab, Anakinra and Tocilizumab in patients with non-infectious Uveitis: A multicenter randomized controlled trial

Key Points

• Patients receiving adalimumab demonstrated significant improvement in uveitis symptoms compared to the control group, leading to faster recovery.
• In the trial involving 120 participants, 65% of those on adalimumab achieved desired outcomes within six months.
• Multicenter randomized controlled trial assessed three different therapies for non-infectious uveitis, highlighting their specific effects.
• These findings support the potential of adalimumab, anakinra, and tocilizumab as effective treatments for managing uveitis.